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Abstract
Gangliosidoses are a heterogeneous group of lysosomal storage diseases with an au-
tosomal recessive trait, which are characterized by the intracellular accumulation of 
gangliosides in several tissues, mainly in neurons. This condition causes a progressive 
neurodegenerative disorder with varied clinical presentations. Depending on the seve-
rity of the enzymatic defect, gangliosidoses show different rates of clinical progression 
and organ involvement; poor residual enzyme activity is seen in more aggressive forms 
(infantile and juvenile subtypes) leading to early death whereas cases with better 
residual enzyme activity have a late onset in adult life and a milder clinical course. 
Autopsy findings of a 7 month-old girl with histological and ultrastructural changes 
consistent with gangliosidosis are presented.
Caso mortal de enfermedad de almacenamiento lisosomal en una niña de 7 meses
Resumen
Las gangliosidosis son un grupo heterogéneo de enfermedades de almacenamiento li-
sosomal que se heredan con carácter autosómico recesivo y se caracterizan por la 
acumulación intracelular de gangliósidos en distintos tejidos, principalmente en las 
neuronas. La condición causa un trastorno neurodegenerativo progresivo con presen-
taciones clínicas variadas. Las gangliosidosis exhiben diferente evolución clínica y 
compromiso orgánico dependiendo de la gravedad del defecto enzimático; en las for-
mas más agresivas (subtipos infantil y juvenil) se observa escasa actividad enzimática 
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Case presentation
The patient was a 7 month-old girl product of the third 
pregnancy of non-consanguineous parents, whose deli-
very was uneventful. The patient had been initially seen 
by a pediatrician because of macrocephalia and psycho-
motor delay; no definitive diagnosis had been made. 
Family history was negative. The patient was first seen at 
the pediatric emergency room of our institution becau-
se of a febrile respiratory illness. Physical examination, 
routine lab tests, and a chest x-ray confirmed the diag-
nosis of pneumonia; rapid influenza A test was positive. 
The patient was admitted to the pediatrics service where 
medical management was initiated. During the second 
day of admission, she suddenly developed vomiting, neu-
rologic collapse, metabolic acidosis, hypotension, and 
cardiopulmonary arrest, and was unresponsive to resus-
citation maneuvers.
A complete autopsy was performed. Weight and height 
were within normal limits. On external examination, both 
coarse face and depressed nasal bridge were identified. 
In situ inspection of the pelvic organs was unremarkable. 
The lungs showed gross changes consistent with pneumo-
nia. Hepatosplenomegaly was present. The brain weighed 
831 g (normal weight according to age/height: 691 g). The 
most significant gross finding on autopsy was the presence 
of enlarged convolutions of the frontal and parietal cere-
bral cortex; sulci also appeared short and scanty (Figure 
1). These features were more evident on cut surface. The 
ventricular system, the brain stem, and the cerebellum 
showed no abnormalities. Except for the eyes, routine 
representative sections of the organs were submitted 
for histology. The initial histopathological study demons-
trated bilateral acute pneumonia as the direct cause of 
death. Sections from the central nervous system (CNS), 
the spinal cord, and sympathetic ganglia from the para-
vertebral region showed that neurons presented severe 
morphological changes. The most striking degenerative 
changes consisted in neuronal enlargement with broad 
dendritic processes lacking slender cellular borders. The 
normal appearance of the cytoplasm was replaced by 
a large amount of granular material leading to swollen 
neurons with displaced nuclei (Figure 2); the intracyto-
plasmic material was positive for periodic acid-Schiff 
stain with diastase digestion and luxol fast blue. In addi-
tion, both astrogliosis in the brain cortex and spinal cord 
and ectopic neurons in the cerebellum were seen. Similar 
cytoplasmic changes were identified in interalveolar and 
gastrointestinal macrophages. The thymus, the spleen, 
the liver, and the heart were also affected. Tissue from 
the CNS and the lungs was submitted for electron microsco-
py. Ultrastructural study demonstrated numerous whorled 
membranous and stacked intracytoplasmic structures 
(Figure 3), which represent massive accumulation of gly-
colipids. Through histological and ultrastructural findings 
besides the clinical picture, the diagnosis of a lysosomal 
storage disease affecting the CNS and viscera consistent 
with infantile generalized gangliosidosis was made. 
Discussion 
Gangliosidoses are a rare and heterogeneous group of 
lysosomal storage diseases inherited with an autosomal 
recessive trait; the metabolic disorder is caused by mu-
tatations in any of the genes encoding enzymes involved 
in gangliosides metabolism. The deficiency of enzyme ac-
tivity leads to accumulation of gangliosides and related 
glycoconjugates in the lysosomes, which causes lysoso-
mal swelling, cellular damage, and organ dysfunction, 
primarily in the CNS1,2 but also in viscera.3,4 In 1942, 
Klenk identified a new class of carbohydrate-rich glyco-
lipids which he named gangliosides and from which fatty 
acids, sphingosine, galactose, glucose, and sialic acid 
were isolated through hydrolysis; the gangliosides also 
contain hexosamine.5 Glycosphingolipids, which are es-
sential components of every eukaryotic cell membrane, 
are synthesized in the endoplasmic reticulum and the 
Golgi apparatus and reside mainly on the external leaflet 
of the plasma membrane; they are internalized by endo-
cytosis and are degraded in the lysosomes. Although once 
considered to be only a structural part of the plasma mem-
brane, these molecules are now known to play important 
roles in a large number of regulatory events in adult life 
such as cell-to-cell and cell-matrix interactions. It is also 
thought that they are involved in many morphogenesis 
processes including cell signaling, growth, migration, and 
residual, lo que conduce a la muerte temprana, mientras que en los casos con mejor 
actividad enzimática residual la presentación ocurre más tardíamente en la adultez y la 
enfermedad tiene un curso clínico más leve. Se presentan los hallazgos de la autopsia 
de una niña de 7 meses con cambios histológicos y ultraestructurales de gangliosidosis.
Figure 1. Gross photograph of coronal section of the brain; 
note the broad convolutions and short sulci.
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differentiation.6 As gangliosides are seen at the highest 
level of brain tissue, progressive neurological involve-
ment is the rule. Genetic deficiency of lysosomal enzyme 
is varied; consequently, biochemical changes produce a 
significant heterogeneity in phenotypic expression. The 
progression of the disease depends largely on the nature 
of the mutation and its effect on enzyme activity. Muta-
tions on the gene GLB1 which maps to the short arm of 
chromosome 3, encode the β-galactosidase enzyme and 
cause GM1 gangliosidosis and Morquio B disease,7,8,9,10 whe-
reas mutations on the HEXA gene (code for a-hexosaminidase 
subunit-α) and the HEXB gene (code for b-hexosaminidase 
subunit-β) produce the GM2 gangliosidoses Tay-Sachs disease 
and Sandhoff disease, respectively; mutations on the GM2A 
gene result in GM2 activator deficiency.11,12,13 Clinical 
presentation, organ involvement, and age of onset show 
significant heterogeneity ranging from infantile-onset, 
rapidly progressing neurological damage, and premature 
death to late-onset, sub-acute, juvenile-onset, and chro-
nic or adult forms with fewer neurological manifestations 
(Table 1).1,14-16 The severity of each subtype is inversely 
related to the residual activity of the mutant enzyme.1,11 
However, the sine qua non of the disease is the progressive 
neurodegenerative damage that may culminate in death 
in the most aggressive forms of the disease.17 Gangliosi-
doses are extraordinary diseases for which a panethnic 
background has been reported; increasing prevalence 
has been identified in Brazil, Japan, Malta, Cyprus, and 
among Jewish Ashkenazi and in Roma population.18,19,20 
The incidence of GM1 and GM2 gangliosidoses has been 
estimated to be 1 in 100,000–200,000 live births1 and 1 in 
222,000-422,000 live births,2 respectively. The diagnosis 
of a neurodegenerative disorder with an inherited meta-
bolic background is not simple and relies mainly on a high 
index of suspicion and the clinical experience since most 
cases present with common pediatric problems such as 
recurrent vomiting, failure to thrive, seizures, deve-
lopmental delay, and recurrent infections; nevertheless, 
several clinical features may suggest a lysosomal storage 
disease (Table 2).1,15,21 Lysosomal storage diseases share a 
common feature i.e., the biochemical disorder resulting 
in the accumulation within the lysosomes of normally de-
graded substrates. Skin and suction rectal biopsies are 
useful tools to elucidate the ultrastuctural nature of the 
accumulated substrate.22-24 A definitive diagnosis is rea-
ched through enzyme assays and molecular biology.16,25 
Imaging may also positively contribute to the diagnosis.26 
In the described case, clinical features of the patient 
were mild; however, post-mortem findings including light 
and electron microscopy were unequivocal. The neurons 
of the CNS appeared swollen with accumulation of glycoli-
pids; a mild inflammatory process, gliosis, meganeurites, 
and neuronal ectopia were all observed. The histologi-
cal changes seen in this case have been reported in the 
literature and are thought to account for the neuronal 
dysfunction. Despite this, the underlying mechanisms 
of the disease are not completely understood. Neuro-
nal apoptosis, astrogliosis, microgliosis, demyelination, 
abnormal axoplasmic transport, and alteration in neuro-
nal-oligodendroglial interactions have all been proposed 
as possible mechanisms of pathogenesis.27 More recently, 
the inflammatory response has been thought to contri-
bute to the pathogenesis and disease progression.28,29 In 
animal models the accumulation of gangliosides acti-
vates microglia, which in turn recruit macrophages and 
T-lymphocytes initiating the inflammatory response.30 
Gangliosidosis is currently an incurable disease and only 
support therapy is available; different therapeutic strate-
gies have been explored including enzyme replacement, 
substrate deprivation, bone marrow transplantation, and 
gene therapy.31-33 Experiments in animal models using gene 
therapy and viral vectors have brought new hope for 
these patients.34,35 In the present case, the clinical and 
laboratory diagnostic approach was not completed since 
the patient had been admitted because of an acute res-
piratory disease and a lysosomal storage disease was not 
Figure 2. A group of swollen neurons are seen in this picture, 
gliosis (upper left) and meganeurites also are identified (in-
set). Hematoxilin & Eosin.
Figure 3. Numerous membranous lamellar bodies are seen in 
this Ultrastructure.
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Table 1. Clinical, molecular and microscopic features of GM1 and GM2 gangliosidoses.
Disease Enzyme Gene Phenotype Pathology
GM1 Gangliosidosis 
Infantile type I
Juvenile type II
Adult type III
b-Galactosidase GLB1 Macro/microcephalus, dysmorphic face, 
melanocytosis, skeletal defects, hypotonia, macular 
cherry-red spot, hepatosplenomegaly, psychomotor 
delay. Death before age 4
Less dysmorphic features, slow progression of 
neurological symptoms, ataxia, dysarthria, seizures, 
no visceral involvement, lifespan 3-10 years
Normal early neurological development, no stigmata, 
onset of neurological symptoms in adolescence, 
speech and gait disturbances, dystonia, Parkinson, 
dementia
Vacuolated lymphocytes, 
macrophages and neurons, gliosis, 
inflammation, membranous lamellar 
cytoplasmic bodies identifiable by 
ultrastructural imaging
GM2 Gangliosidoses 
Tay-Sachs disease
Acute infantile 
Juvenile sub-acute
Adult chronic
Sandhoff disease
Infantile
Late juvenile and adult
GM2 activator protein 
deficiency
b-hexosaminidase A 
b-hexosaminidase AB 
GM2 activator protein
HEXA
HEXB
GM2A
Neurological symptoms by age 3-6 months, 
exaggerated startle, abnormal psychomotor 
development, macular cherry-red spot, blindness, 
deafness, life span 4-5 years
Progressive neurologic deterioration, loss of motor 
and spinocerebellar functions, gait and speech 
impairment
Normal neurologic development, spinocerebellar 
degeneration, dystonia, ataxia, atrophy, psychiatric 
symptoms
Similar to Tay-Sachs disease, hepatosplenomegaly, 
skeletal abnormalities
Adult onset, slow progression, postural dystonia, 
seizures
Clinical course similar to infantile Tay-Sachs disease
Vacuolated neurons, gliosis, 
meganeurites, membranous 
lamellar/stacked cytoplasmic bodies 
identifiable by ultrastructural imaging
Table 2. Clinical features associated to neurodegenerative disorders with metabolic background.
Dysmorphic features present 
at birth
Coarse face, depressed nasal bridge, craniofacial and limb dysostosis, low-set ears, corneal clouding, macular cherry-red 
spot 
Central nervous system Delay/arrest of psychomotor development, neurological regression, seizures, blindness, deafness, distonia, extrapyramidal/
spinocerebellar symptoms, psychiatric problems
Systemic findings Bone marrow depression, hepatosplenomegaly, vacuolated lymphocytes, repeated infections, cardiomyopathy, frequent 
vomiting, constipation, failure to thrive, skeletal abnormalities
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suspected; however, from an anatomopathological point 
of view, a differential diagnosis was carried out. Lyso-
somal storage diseases (affecting the CNS and viscera) 
other than gangliosidoses such as Niemann Pick disease 
and Gaucher’s disease were ruled out since the clinical pic-
ture, the extension of the disease, and the histological 
and ultrastructural features were more consistent with a 
gangliosidoses. 
Conclusion 
Gangliosidoses are inborn errors of metabolism resulting 
from the defective activity of degradative enzymes in 
lysosomes and causing a neurodegenerative disorder. The 
diagnosis relies on clinical suspicion, imaging, light and 
electron microscopy, and enzyme assays or molecular bio-
logy. Reaching a correct diagnosis is of utmost importance 
for appropriate therapy and genetic counseling.
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